

# Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad – 500 095.


Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

## STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER,14

(Rs. in Lakhs)

### PART - I

S. No	Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2014	30.06.2014	30.09.2013	30.09.2014	30.09.2013	31.03.2014
		Un-audited					Audited
<b>1</b>	<b>Income from Operations</b>						
	(a) Net Sales/Income from operations	45.29	45.17	28.38	90.46	55.51	140.52
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total Income from Operations</b>	<b>45.29</b>	<b>45.17</b>	<b>28.38</b>	<b>90.46</b>	<b>55.51</b>	<b>140.52</b>
<b>2</b>	<b>Expenses</b>						
	a. Consumption of raw materials	1.55	2.91	1.92	4.46	3.03	0.00
	b. Purchases of stock-in-trade	25.14	21.25	18.72	46.39	34.69	103.94
	c. Increase/decrease in stock in trade and WIP	3.03	(2.09)	(1.32)	0.94	1.81	(5.52)
	d. Power & Fuel	0.00	0.00	0.00	0.00	0.00	0.00
	e. Sales Tax and other Taxes	0.00	0.00	0.00	0.00	0.00	0.00
	f. Employees Cost	4.87	4.44	2.54	9.31	4.40	9.55
	g. Depreciation	1.68	1.68	2.00	3.36	4.00	8.00
	h. Other expenditure	11.65	22.82	4.53	34.47	10.11	76.18
	<b>Total</b>	<b>47.92</b>	<b>51.01</b>	<b>28.39</b>	<b>98.93</b>	<b>58.04</b>	<b>192.15</b>
	(Any item exceeding 10% of the total expenditure to be shown separately)	0.00	0.00	0.00	0.00	0.00	0.00
<b>3</b>	<b>Profit / (Loss) from Operations before other Income, finance costs and Exceptional Items (1-2)</b>	<b>(2.63)</b>	<b>(5.84)</b>	<b>(0.01)</b>	<b>(8.47)</b>	<b>(2.53)</b>	<b>(51.63)</b>
<b>4</b>	<b>Other Income</b>	<b>4.95</b>	<b>7.58</b>	<b>3.03</b>	<b>12.53</b>	<b>7.53</b>	<b>15.84</b>
<b>5</b>	<b>Profit / (Loss) from Ordinary activities before finance costs and exceptional items</b>	<b>2.32</b>	<b>1.74</b>	<b>3.02</b>	<b>4.06</b>	<b>5.00</b>	<b>(35.79)</b>
<b>6</b>	<b>Finance Cost</b>	<b>0.00</b>	<b>0.00</b>	<b>0.17</b>	<b>0.00</b>	<b>0.34</b>	<b>0.81</b>
<b>7</b>	<b>Profit / (Loss) from Ordinary activities after finance costs but before exceptional items</b>	<b>2.32</b>	<b>1.74</b>	<b>2.85</b>	<b>4.06</b>	<b>4.66</b>	<b>(36.60)</b>
<b>8</b>	<b>Exceptional Items - Expenditure / (Income)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>9</b>	<b>Profit / (Loss) from Ordinary</b>	<b>2.32</b>	<b>1.74</b>	<b>2.85</b>	<b>4.06</b>	<b>4.66</b>	<b>(36.60)</b>
<b>10</b>	<b>Tax expense</b>						
	a) Provision for Taxation	0.00	0.00	0.00	0.00	0.00	0.00
	b) Provision for Deferred tax	0.00	0.00	0.00	0.00	0.00	(1.17)
	c) MAT Credit	0.00	0.00	0.00	0.00	0.00	0.00
<b>11</b>	<b>Net Profit (+)/ Loss (-) from ordinary activities after tax</b>	<b>2.32</b>	<b>1.74</b>	<b>2.85</b>	<b>4.06</b>	<b>4.66</b>	<b>(35.43)</b>
<b>12</b>	<b>Extraordinary items (net of tax expense Rs.Nil)</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>
<b>13</b>	<b>Net Profit (+)/Loss (-) for the period</b>	<b>2.32</b>	<b>1.74</b>	<b>2.85</b>	<b>4.06</b>	<b>4.66</b>	<b>(35.43)</b>
<b>14</b>	<b>Paid-up equity share capital (Face value of the Share is Rs 10/- each)</b>	<b>336.31</b>	<b>336.31</b>	<b>336.31</b>	<b>336.31</b>	<b>336.31</b>	<b>336.31</b>
<b>15</b>	<b>Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	<b>9.94</b>	<b>9.94</b>	<b>9.94</b>	<b>9.94</b>	<b>9.94</b>	<b>9.94</b>
<b>16</b>	<b>Earnings Per Share (before extraordinary items - not annualised)</b>						
	a) Basic	0.07	0.05	0.08	0.12	0.14	(1.04)
	b) Diluted	0.07	0.05	0.08	0.12	0.14	(1.04)





17	Earnings Per Share (after extraordinary items - not annualised)						
a)	Basic	0.07	0.05	0.08	0.12	0.14	(1.04)
b)	Diluted	0.07	0.05	0.08	0.12	0.14	(1.04)

**PART - II**

**A. Particulars of Shareholding**

1	Public shareholding						
	- Number of shares	3174393	3166405	3166405	3166405	3166405	3166405
	- Percentage of shareholding	93.21%	92.98%	92.98%	92.98%	92.98%	92.98%
2	Promoters and Promoter Group Shareholding						
a	Pledged/Encumbered - No. of percentage of shares	NIL	NIL	NIL	NIL	NIL	NIL
	(as a % of the total shareholding of promoter and promoter group)						
	percentage of shares	NIL	NIL	NIL	NIL	NIL	NIL
	(as a % of the total share capital)						
b	Non - encumbered						
	Number of shares	231107	239095	239095	239095	239095	239095
	percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	percentage of shares (as a % of the total sharecapital of the company)	6.79%	7.02%	7.02%	7.02%	7.02%	7.02%

B.	Particulars	3 months ended 30/09/2014
	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil


**Notes:**

- The above results have been reviewed by the Audit Committee and taken on by the Board at its Meeting held on 15th day of November 2014.
- Figures for the previous Year/Quarter/ Half yearly have been rearranged / regrouped wherever necessary.
- The Company's exclusive business is manufacturing and selling of Drugs Formulation and as such this is the only reportable segment as per Accounting Standard - 17 on segment reporting issued by the ICAI
- Provisions for Income Tax and Differed Tax will be made at the end of the Financial Year
- During this quarter the Company has adopted the useful life of Fixed assets as indicated in Schedule II of Companies Act 2013 effective from 1st April 2014, as result the depreciation charge for the half year ended September 30, 2014 is higher by Rs.0.68 lakhs. Carrying value of assets amounting to Rs.3.36 lakhs which has completed its useful life period as on 01.04.2014 is adjusted against the accumulated balance of Retained earnings (deficit).

For PHARMAIDS PHARMACEUTICALS LIMITED

*Chandru*  
Dr. Ghisulal Jain  
Chairman & Managing Director

PLACE : HYDERABAD  
DATE :15.11.2014





Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad - 500 095.

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 30.09.2014

(Rs. In lakhs)

	Particulars	As on 30.09.2014	As on 31.03.2014
		Audited	Audited
<b>A</b>	<b>EQUITY AND LIABILITY</b>		
<b>1</b>	<b>SHARE HOLDERS' FUNDS:</b>		
	(a) Share Capital	336.31	336.31
	(b) Reserves and Surplus	-154.13	-154.83
	<b>Sub Total - Shareholders Fund</b>	<b>182.18</b>	<b>181.48</b>
<b>2</b>	<b>Share application money pending allotment</b>	<b>0.00</b>	<b>0.00</b>
<b>3</b>	<b>Minority Interest</b>	<b>0.00</b>	<b>0.00</b>
<b>4</b>	<b>Non-Current Liabilities</b>		
	(a) Long term Borrowings	33.31	33.81
	(b) Deferred Tax (Net)	10.23	10.23
	(c) Other Long term Liabilities	0.00	0.00
	(d) Long Term Provisions	0.00	0.00
	<b>Sub-Total - Non Current Liabilities</b>	<b>43.54</b>	<b>44.04</b>
<b>5</b>	<b>Current Liabilities</b>		
	(a) Short Term Borrowings	0.00	2.18
	(b) Trade Payables	49.24	52.77
	(c) Other Current Liabilities	8.50	9.25
	(d) Short Term Provisions	0.00	0.00
	<b>Sub-Total - Current Liabilities</b>	<b>57.74</b>	<b>64.20</b>
	<b>TOTAL EQUITY AND LIABILITY</b>	<b>283.46</b>	<b>289.72</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(A) Fixed Asset	56.30	61.88
	(b) Non Current Investment	0.00	0.00
	(c) Deferred Yax Asset (Net)	0.00	0.00
	(d) Long term Loans and Advances	0.00	57.90
	(e) Other Non-Current Assets		
	<b>Sub-Total Non-Current Assets</b>	<b>56.30</b>	<b>119.78</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Current Investments	0.00	0.00
	(b) Inventories	26.51	28.22
	(c) Trade Receivables	120.75	125.61
	(d) Cash and Cash equivalents	24.32	12.65
	(e) Short Term Loans and Advances	55.58	0.00
	(f) Other Current Assets	0.00	3.46
	<b>Sub-Total Current Assets</b>	<b>227.16</b>	<b>169.94</b>
	<b>TOTAL</b>	<b>283.46</b>	<b>289.72</b>


For PHARMAIDS PHARMACEUTICALS LIMITED

PLACE : HYDERABAD

DATE : 15.11.2014

Dr. Ghisulal Jain

Chairman & Managing Director







**RAKESH S JAIN & ASSOCIATES**  
CHARTERED ACCOUNTANTS

14-6-191, Nagar Khana, Begum Bazar,  
HYDERABAD - 500 012. (A.P.) INDIA

E-mail : [rsjainassociates@rediffmail.com](mailto:rsjainassociates@rediffmail.com)

Phone : 040-24614481, Fax : 040-24617420

Suresh Kumar Jain (Mob) : +91-9849025612

B. Ramesh Kumar (Mob) : +91-9849025641

Date :

### LIMITED REVIEW REPORT

We have reviewed the accompanying statement of un-audited financial results of Pharmaids Pharmaceuticals Limited for the quarter ended 30-09-2014 except for the disclosures regarding Public Shareholding and Promoter Group Shareholding which has been traced from disclosures made by the management and has not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an opinion. We have not performed an audit and accordingly we do not express such an opinion.

Management has informed to us being quarterly closing, the company has not accounted for taxes on income as required under AS-22 i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end.

Based on our review conducted as above, and subject to the points mentioned above, nothing has come to our notice that causes us to believe that the accompanying statement of un-audited financial results in accordance with applicable accounting standards and other recognized accounting policies and practices has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For RAKESH S JAIN & ASSOCIATES

Chartered Accountants

Firm Registration No. 010129S

Date: 15.11.2014  
Place: Hyderabad.

*B. Ramesh Kumar*  
  
(B. RAMESH KUMAR)  
Partner  
M. No. 200304